Savara Advances Pipeline of Inhaled Therapeutics for Rare Lung Diseases
December 29, 2017
PAP and NTM are two rare lung conditions with different pathologies. PAP is an autoimmune condition while NTM is caused by a bacterial infection. Savara Pharmaceuticals is developing an inhaled therapeutic it thinks can treat each of these two different conditions. We spoke to Rob Neville, co-founder and CEO of Savara, about the company, its lead therapeutic Molgradex, and what a recent grant from the Cystic Fibrosis Foundation will mean to advancing another candidate in its pipeline.
Sign up for updates straight to your inbox.